Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietType 2 DiabetesAging & DiabetesIssue 612

Decaffeinated Coffee Might Boost Brain Power for Type 2 Diabetes

Decaf coffee was found to improve glucose energy metabolism in the brain in mouse studies....

Advertisement

Type 2 diabetes is linked to cognitive decline, dementia and Alzheimer's disease that stems from impaired breakdown of glucose needed for optimal brain function. The study is the first to show decaffeinated coffee might prevent and treat declining memory associated with Type 2 diabetes, aging and neurodegenerative disorders.

For the study researchers gave mice induced to develop diabetes a decaf coffee supplement for five months and then evaluated the mouse brain's genetic response to the treatment. The result was increased ability of the brain to metabolize glucose.

Giulio Maria Pasinetti, MD, PhD, Professor of Neurology, and Psychiatry, at Mount Sinai School of Medicine, said it's important to find ways to prevent cognitive decline from neurodegenerative diseases. Studies show pathological changes in the brain occur decades before Alzheimer's and other diseases develop. He also notes the study shows not all of the health benefits associated with coffee come from caffeine.

It's important to note that coffee can have negative cardiovascular effects and is linked to elevated blood pressure and cholesterol levels, making consumption risky for some.

Pasinetti plans to explore whether decaffeinated coffee could be useful as a dietary supplement in humans to prevent or even treat memory loss associated with Type 2 diabetes and other brain disorders.

Nutritional Neuroscience H. Lap et al.Nov. 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 08 February, 2012 and appeared in  DietType 2 DiabetesAging & DiabetesIssue 612

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Are Postprandial Levels in T1 Patients Impacted by More Than Carbohydrates?
Posted May 28, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology